Indigo Diabetes concludes a €38 million round of financing
- Indigo Diabetes concludes a €38 million round of financing to advance development of ground-breaking sensor for diabetes
- Second investment of the Capricorn Digital Growth Fund
- Invisible sensor for people with diabetes aims at measuring multiple metabolites
Ghent, Belgium: 27 July 2020 – Indigo Diabetes nv, a young high-tech medical device company that develops medical solutions using nanophotonics, today announced the conclusion of a €38 million Series B funding round to further develop its promising Multi-Biomarker Sensor for people with diabetes. The funding round was led by Fund+, with the participation of Ackermans & van Haaren, imec.xpand, Capricorn Digital Growth Fund, QBICII, Titan Baratto and the Series A investors, including Capricorn ICT Arkiv.
The new investment round will enable Indigo Diabetes to prepare and start up the clinical study phase. The small sensor chip is designed to be inserted underneath the skin and continuously measure glucose and ketones in people with diabetes. The latter is a worldwide first and aims at enabling the faster detection of life-threatening situations by both the users and their healthcare providers. At the same time, the invisible sensor strives to afford patients a substantially improved quality of life.
More information on Indigo Diabetes’ website.